Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.

Abstract

PURPOSE OF REVIEW:

The review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the American College of Cardiology 2020 Virtual Scientific Session (ACC.20)/World Cardiology Congress (WCC).

RECENT FINDINGS:

The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA]). In addition, results from the pooled analysis of phase III trials on inclisiran and secondary analysis examining eicosapentaenoic acid levels and cardiovascular outcomes from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) were included. Finally, we discuss studies examining the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. The studies presented at the ACC.20/WCC represent notable contributions in the field of CVD prevention.

• Authors: Xiaoming Jia, Mahmoud Al Rifai, Jing Liu, Anandita Agarwala, Martha Gulati, Salim S Virani
• Journal: Current atherosclerosis reports (Curr Atheroscler Rep) Vol. 22 Issue 8 Pg. 32 (06 18 2020) ISSN: 1534-6242 [Electronic] United States
• PMID: 32556778 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Cholesterol, LDL
• Heterocyclic Compounds, 2-Ring
• Pyrimidines
• eicosapentaenoic acid ethyl ester
• Eicosapentaenoic Acid
• vericiguat
• evinacumab

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (therapeutic use)
• Child
• Cholesterol, LDL (blood)
• Denervation (methods)
• Eicosapentaenoic Acid (analogs & derivatives, therapeutic use)
• Electronic Nicotine Delivery Systems
• Female
• Heart Failure (drug therapy)
• Heterocyclic Compounds, 2-Ring (therapeutic use)
• Humans
• Hyperlipoproteinemia Type II (drug therapy)
• Hypertension (blood, surgery)
• Kidney (surgery)
• Male
• Middle Aged
• Pyrimidines (therapeutic use)
• Randomized Controlled Trials as Topic
• Smoking Cessation (methods)
• United States
• Young Adult